Who Owns Tylenol?

As a pharmaceutical product, Tylenol's sustainability profile focuses primarily on packaging and manufacturing practices. Kenvue has committed to achieving net zero greenhouse gas emissions across its value chain by 2050, with interim targets for 2030.

Packaging: Kenvue has pledged to reduce virgin plastic use in packaging by 25 percent by 2025 and 50 percent by 2030, using 2020 as the baseline year. Tylenol packaging has evolved to reduce environmental impact, with efforts to minimize plastic use and increase recyclability. However, pharmaceutical packaging faces unique constraints due to safety, tamper-resistance, and regulatory requirements.

Manufacturing: Kenvue has invested in renewable energy for production facilities and implemented water conservation measures. The company publishes annual sustainability reports detailing progress on environmental goals, including waste reduction and renewable energy adoption.

Medication Disposal: Kenvue participates in pharmaceutical industry initiatives for responsible medication disposal to prevent environmental contamination.

Animal Testing: Tylenol does not carry cruelty-free or vegan certifications, as pharmaceutical products undergo regulatory testing that may involve animal studies as required by FDA approval processes.

Legal and Ethical Challenges: The ongoing autism and ADHD litigation has created significant reputational challenges for Tylenol. Kenvue has consistently maintained that Tylenol is safe when used as directed, emphasizing decades of scientific research supporting the product's safety profile. The company has pledged to defend against what it considers unfounded claims.

• Pharmacy Times OTC Survey: Tylenol has been consistently ranked as the number one pharmacist-recommended brand for pain relief and fever reduction in annual Pharmacy Times surveys.
• Brand Finance Pharma 50: Tylenol has been ranked among the most valuable pharmaceutical brands globally by Brand Finance in annual brand valuation reports.
• Harris Poll EquiTrend Study: Tylenol has received high rankings in consumer brand equity studies measuring trust, quality perception, and consideration among OTC pain relief brands.
• FDA Approval for Tylenol with Naproxen (2026): Kenvue received FDA approval for the first and only OTC fixed-dose combination of acetaminophen and naproxen sodium, building on over 70 years of Tylenol leadership in pain relief innovation.

1982 Tylenol Poisoning Crisis: In September and October 1982, seven people in the Chicago area died after taking Extra-Strength Tylenol capsules that had been laced with potassium cyanide. Johnson and Johnson's response included an immediate nationwide recall of 31 million bottles valued at over $100 million and introduction of tamper-resistant packaging. Tylenol recovered market leadership within a year.

2010-2011 Product Recalls: Between 2009 and 2011, Johnson and Johnson conducted multiple voluntary recalls of Tylenol and other McNeil products due to manufacturing quality issues at its Fort Washington, Pennsylvania facility. Issues included musty odor from packaging materials, presence of metal particles, and bacterial contamination. The Fort Washington plant was temporarily shut down for remediation.

Acetaminophen Dosage and Liver Safety: In 2009, an FDA advisory panel recommended reducing the maximum single adult dose of acetaminophen from 1,000 mg to 650 mg due to concerns about liver damage from overdose. In 2011, McNeil Consumer Healthcare voluntarily reduced the maximum daily dose listed on Extra Strength Tylenol from 4,000 mg to 3,000 mg.

Texas Attorney General Lawsuit (October 2025): Texas Attorney General Ken Paxton sued Kenvue on October 28, 2025, accusing the company of violating Texas' Deceptive Trade Practices Act by failing to warn consumers that Tylenol may be unsafe for pregnant women and potentially linked to autism and ADHD. In February 2026, a Texas judge rejected Kenvue's bid to dismiss the lawsuit. Paxton also sought to block Kenvue's $398 million shareholder dividend payment, but a Texas judge cleared the way for the payment in November 2025.

Private Autism Lawsuits Revived (July 2026): On July 13, 2026, the 2nd U.S. Circuit Court of Appeals in Manhattan revived over 500 private lawsuits against Kenvue alleging Tylenol use during pregnancy causes autism and ADHD. Circuit Judge Guido Calabresi wrote that the testimony from three doctors reflected methodologies used by other scientists and constituted acceptable interpretations of scientific evidence. The decision returns the lawsuits to U.S. District Judge Denise Cote for further proceedings. Kenvue shares fell to $19.28 following the decision. Kenvue stated that the science has not changed.

FDA Labeling Controversy (2025): The FDA considered new labeling requirements for acetaminophen products after growing evidence suggested potential links between use during pregnancy and developmental disorders. In September 2025, the FDA told doctors to alert patients about emerging concerns. Kenvue pushed back against proposed label changes, arguing they were unsupported by scientific evidence and violated the company's First Amendment rights.

Political Pressure (2025): President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. publicly suggested links between Tylenol and autism, creating political pressure on Kenvue and regulatory agencies. The administration's involvement elevated the controversy to national attention.

Scientific Community Response: Medical societies, including the American College of Obstetricians and Gynecologists, have issued statements reassuring pregnant women that Tylenol is safe for use when needed, though they recommend consulting healthcare providers about medication use during pregnancy.